# To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy.

> **NCT07081256** · PHASE3 · COMPLETED · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 665 (actual)

## Conditions studied

- Chemotherapy-Induced Nausea and Vomiting

## Interventions

- **DRUG:** QLM2010 for injection；dexamethasone
- **DRUG:** fosaprepitant dimeglumine for injection；palonosetron hydrochloride injection；dexamethasone

## Key facts

- **NCT ID:** NCT07081256
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-01-03
- **Primary completion:** 2025-08-25
- **Final completion:** 2025-10-15
- **Target enrollment:** 665 (ACTUAL)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07081256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07081256, "To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07081256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*